Why is Moderna stock down today?

Traders Union
All News
Financial News
Moderna slides 2.27% today to $46.53

Highlights

Moderna advanced its mRNA Lyme disease vaccine to Phase 2 trials and began early research on a hantavirus vaccine with U.S. and Korean partners.
The company’s mRNA flu vaccine will be discussed at an FDA advisory meeting on June 18, potentially influencing future regulatory momentum.
Moderna trades below key moving averages under short-term selling pressure, with expectations for consolidation between $44.77 and $47.70 over the next five days.

Pipeline updates and partnerships fail to offset ongoing bearish sentiment

Moderna announced early-stage research into an mRNA-based hantavirus vaccine in partnership with the U.S. Army Medical Research Institute of Infectious Diseases and Korea University through its mRNA Access Program. The company reported that its mRNA Lyme disease vaccine has advanced to Phase 2 clinical trials. Moderna's mRNA flu vaccine is also scheduled for discussion at an FDA advisory committee meeting on June 18, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees persistent weakness in Moderna’s short- and medium-term structure. He notes sustained selling pressure below key moving averages, limited by only long-term support at $37.26. News on vaccine research and trial progression has not translated to fresh momentum. Technical indicators remain mixed with daily MACD negative and an ADX reading under 15 reflecting indecisive direction. "Unless Moderna can break above $47.70 and demonstrate clear trend strength, I see little reason to expect a durable rally in the coming week."

Viktoras Karapetjanc, expert at Traders Union, highlights Moderna’s expanding mRNA pipeline and partnerships as reinforcing its fundamental outlook. He stresses that the advance of the Lyme and flu vaccines sustain growth potential, regardless of short-term price dips. Technicals confirm the bullish structure remains intact above the 200-day moving average. "With the weekly setup turning strongly positive and robust product news flow, further growth is likely if Moderna holds above support and clears $47.70."

Parshwa Turakhiya, analyst, observes that Moderna’s sentiment is mixed but leaning defensive after the recent price gap and intraday volatility. Oscillators show indecision, with Stochastic RSI hinting at potential short-term rebound while MACD stays negative. He sees trading opportunities between $44.77 and $47.70 until the market chooses a clear direction. "Traders should watch for rapid shifts in sentiment, since both breakdown and breakout setups could emerge in the next few sessions."

Mixed momentum signals amid intraday volatility and unresolved technical levels

Moderna remains below its 20-day ($48.45) and 50-day ($50.40) moving averages, reflecting short- and medium-term selling pressure, but still trades above its longer-term 200-day level ($37.26), which suggests sustained long-term support. The nearest dynamic resistance comes from the Ichimoku Kijun at $51.59, with no golden or death cross present in the current structure. Momentum readings are mixed. The Moving Average Convergence Divergence (MACD) on the daily chart indicates negative momentum and signals further weakness, while the Average Directional Index (ADX) at 14.99 reflects a lack of strong trend. The Relative Strength Index (RSI) sits at 45.54, favoring a sell scenario, yet the Stochastic RSI is turning up from oversold areas and the Commodity Channel Index (CCI) is neutral. Bull/Bear Power (BBP) is elevated at 0.82, highlighting that buyers continue to dominate intraday action even as the forecast points to overbought conditions. The stock is down 2.27% today, currently trading mid-range at $46.53 after opening with a downside gap of about $0.73. Intraday volatility stands at 2.55%. The intraday tone reflects ongoing pressure since the open, with some divergence between oscillators signaling mixed near-term signals and choppy price action.

Earlier, analysts noted that while Moderna showed persistent short- and medium-term weakness, its long-term outlook was supported by a constructive pipeline and developing initiatives. The latest technical readings and vaccine developments add nuance to this view, with consolidation expected as the prevailing scenario and a breakout above $47.70 serving as the next key inflection point for renewed momentum.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.